DRUGS IN ANESTHESIA: Edited by Eberhard F. KochsRemimazolam for anaesthesia or sedationSneyd, J. Roberta; Rigby-Jones, Ann E.bAuthor Information aFaculty of Health: Medicine, Dentistry and Human Sciences bLecturer in Pharmacology (Education), Faculty of Health: Medicine, Dentistry and Human Sciences, University of Plymouth, Plymouth, UK Correspondence to J. Robert Sneyd, MD, FRCA, Emeritus Professor, Faculty of Health: Medicine, Dentistry and Human Sciences, University of Plymouth, Plymouth, UK. Tel: +44 7870 271531; e-mail: [email protected] Current Opinion in Anaesthesiology: August 2020 - Volume 33 - Issue 4 - p 506-511 doi: 10.1097/ACO.0000000000000877 Buy Metrics Abstract Purpose of review Anaesthesia and sedation are ubiquitous in contemporary medical practice. Developments in anaesthetic pharmacology are targeted on reducing physiological disturbance whilst maintaining or improving titrateability, recovery profile and patient experience. Remimazolam is a new short-acting benzodiazepine in the final stages of clinical development. Recent findings Clinical experience with remimazolam comprises volunteer studies and a limited number of clinical investigations. In addition, laboratory investigations explore the implications of its ‘soft drug’ pharmacology. Summary Remimazolam provides effective procedural sedation with superior success rates and recovery profile when compared to midazolam. Comparisons with propofol are required. Preliminary studies suggest potential for using remimazolam as the hypnotic component of general anaesthesia. Definitive studies are awaited. As a benzodiazepine, remimazolam could be evaluated as an anticonvulsant and for intensive care sedation. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.